AstraZeneca Aktie
WKN: 886455 / ISIN: GB0009895292
|
06.02.2025 23:00:31
|
Why AstraZeneca Topped the Market on Thursday
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as the stock closed the day more than 2% higher in value. This was notably better than the 0.4% bump of the S&P 500 index.AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 2023's figure. On the bottom line the company's "core" (i.e., non-GAAP) earnings per share rose even more sharply, advancing by 44% to $2.09. There was quite some distance between AstraZeneca's performance and analyst estimates for the quarter. On average, pundits following the company were anticipating it would post a lower revenue number ($14.15 billion) and a far lower adjusted net profit of $1.06 per share. Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu The Market Limited Registered Shsmehr Nachrichten
Analysen zu AstraZeneca PLCmehr Analysen
| 25.11.25 | AstraZeneca Sell | Deutsche Bank AG | |
| 14.11.25 | AstraZeneca Outperform | Bernstein Research | |
| 12.11.25 | AstraZeneca Sell | Deutsche Bank AG | |
| 10.11.25 | AstraZeneca Halten | DZ BANK | |
| 10.11.25 | AstraZeneca Outperform | Bernstein Research |
Aktien in diesem Artikel
| AstraZeneca PLC ADR Cert. Deposito Arg. Repr. 2 ADRs | 70 925,00 | 7,14% |
|
| AstraZeneca PLC (spons. ADRs) | 80,00 | -0,62% |
|
| AstraZeneca PLC | 160,30 | -0,12% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.